Published in Lung Cancer on April 17, 2009
Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res (2000) 3.79
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.49
Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer (1987) 2.18
Genetic predisposition to human lung cancer. Br J Cancer (1986) 1.94
Discovery of very-high-energy gamma-rays from the Galactic Centre ridge. Nature (2006) 1.81
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer (1986) 1.45
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
A low level of extragalactic background light as revealed by gamma-rays from blazars. Nature (2006) 1.44
2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. Ann Oncol (1996) 1.43
Interleukin-12 antagonist activity of mouse interleukin-12 p40 homodimer in vitro and in vivo. Ann N Y Acad Sci (1996) 1.42
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer (2006) 1.41
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer (1996) 1.38
Discovery of very high energy gamma rays associated with an x-ray binary. Science (2005) 1.38
The edge-to-edge technique: a simplified method to correct mitral insufficiency. Eur J Cardiothorac Surg (1998) 1.35
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer (2007) 1.33
Preclinical development of a vaccine 'against smoking'. Onkologie (2002) 1.33
Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res (1989) 1.31
Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer. Cancer (1987) 1.26
Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res (2000) 1.24
Breast cancer: pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics. Ann Oncol (1997) 1.22
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). Ann Oncol (1998) 1.20
Multiple sclerosis patients express increased levels of beta-nerve growth factor in cerebrospinal fluid. Neurosci Lett (1992) 1.19
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol (2011) 1.16
Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet (1994) 1.15
Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res (2001) 1.15
Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol (2008) 1.10
Analysis of the multiple interactions between IL-12 and the high affinity IL-12 receptor complex. J Immunol (1998) 1.09
Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis (2005) 1.09
Bilateral internal mammary artery grafting: midterm results of pedicled versus skeletonized conduits. Ann Thorac Surg (1999) 1.06
Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine. Onkologie (2002) 1.05
Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer (2008) 1.05
The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Targets (2010) 1.03
Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol (1996) 0.99
Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol (2000) 0.98
The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (2000) 0.97
Fighting a losing battle: eating-related distress of men with advanced cancer and their female partners. A mixed-methods study. Palliat Med (2007) 0.97
Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Dispos (1996) 0.97
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer (2010) 0.97
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol (2011) 0.95
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol (1989) 0.94
Ifosfamide by continuous infusion to prevent encephalopathy. Lancet (1990) 0.94
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. Br J Cancer (2004) 0.93
A simple quantitative HPLC assay for ifosfamide in biological fluids. Biomed Chromatogr (1986) 0.91
Immunoscintigraphy with 99mTc labelled F(ab')2 fragments of an anti melanoma monoclonal antibody (225.28S) in patients with metastatic malignant melanoma. Eur J Nucl Med (1987) 0.91
Bioavailability of ifosfamide in patients with bronchial carcinoma. Cancer Chemother Pharmacol (1986) 0.90
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol (2006) 0.90
Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol (1997) 0.90
Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol (1994) 0.89
Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res (1991) 0.89
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Ann Oncol (2006) 0.88
Relationships among cell survival, O6-alkylguanine-DNA alkyltransferase activity, and reactivation of methylated adenovirus 5 and herpes simplex virus type 1 in human melanoma cell lines. Cancer Res (1989) 0.88
Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. Drug Metab Dispos (1998) 0.87
Major tumor regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer. Urology (2004) 0.87
Relapse and subarachnoid dissemination of a pineal germinoma 14 years after radiation therapy. J Clin Neurosci (1999) 0.85
The cognitive-spiritual dimension--an important addition to the assessment of quality of life: validation of a questionnaire (SELT-M) in patients with advanced cancer. Ann Oncol (1998) 0.85
Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J Clin Oncol (1995) 0.85
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol (2002) 0.85
Ifosfamide-induced stomatocytosis and mesna-induced echinocytosis: influence on biorheological properties of blood. Eur J Haematol (1999) 0.84
Experiences in the realisation of a research project on anthroposophical medicine in patients with advanced cancer. Schweiz Med Wochenschr (2000) 0.84
Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients. Br J Cancer (2012) 0.83
Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats. Drug Metab Dispos (1998) 0.83
Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. Ann Oncol (1997) 0.83
Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. Eur J Clin Pharmacol (2014) 0.83
High-energy particle acceleration in the shell of a supernova remnant. Nature (2004) 0.82
1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. Ann Oncol (2011) 0.82
Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer. Int J Cancer (1994) 0.82
Elevated carbohydrate antigen 19-9 (CA 19-9) in patients with Echinococcus infection. Clin Chem Lab Med (2001) 0.82
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Ann Oncol (2006) 0.81
Multiple drug resistance parameter expression in ovarian cancer. Gynecol Oncol (1998) 0.81
Autologous peripheral blood stem cell transplantation in a patient with chronic autoimmune thrombocytopenia. Br J Haematol (1997) 0.81
The enigma of ifosfamide encephalopathy. Ann Oncol (1992) 0.81
Discrete improvement in racial disparity in survival among patients with stage IV colorectal cancer: a 21-year population-based analysis. J Gastrointest Surg (2014) 0.81
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol (2010) 0.81
Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy. Ann Oncol (1999) 0.80
Patterns of drug resistance parameters in adult leukemia. Leuk Lymphoma (1995) 0.80
Primary cervical malignant teratoma with a rib metastasis in an adult: five-year survival after surgery and chemotherapy. A case report with a review of the literature. Ann Oncol (1998) 0.80
Effect of in vivo administration of interferon gamma on expression of MHC products and tumour associated antigens in patients with metastatic melanoma. Eur J Cancer Clin Oncol (1989) 0.80
Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Res Clin Oncol (1991) 0.80
Evidence for multiple sites of interaction between IL-12 and its receptor. Ann N Y Acad Sci (1996) 0.80
The proteasome, a new target for cancer therapy. Onkologie (2002) 0.79
The effect of age on the pharmacokinetics of ifosfamide. Br J Clin Pharmacol (1990) 0.79
Phase II studies of 4'-iodo-4'-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers. Ann Oncol (1992) 0.79
[Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration]. Schweiz Med Wochenschr (1989) 0.78
Tracheal granuloma pyogenicum with erlotinib treatment for lung cancer. Eur Respir J (2011) 0.78
Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol (1994) 0.78
Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer. Lung Cancer (2008) 0.78
Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (1995) 0.78
Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. Ann Oncol (1998) 0.78
Cladribine and severe myelotoxicity. Lancet (1993) 0.78
Oral bioavailability of mesna tablets. Cancer Chemother Pharmacol (1993) 0.78
Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK). Br J Haematol (1997) 0.78